Peptides and women's health: what the evidence says for Australian women

Women's hormonal environment changes significantly across life stages — menstrual cycles, perimenopause, and menopause each create distinct physiological contexts that affect how peptide therapy works and what outcomes are achievable. Oestrogen plays a direct role in insulin sensitivity, body fat distribution, bone density, and cognitive function — all areas where peptide therapy intersects. GLP-1 receptor expression is influenced by oestrogen levels, which may partly explain why GLP-1 therapy outcomes differ between pre- and post-menopausal women. Growth hormone secretion patterns in women differ from men — women have more frequent but smaller GH pulses, and GH secretagogue protocols may require different dosing strategies. This guide addresses these distinctions and provides women with an accurate framework for evaluating peptide therapy for their specific situation.

Australia's largest women's GLP-1 program is run by Juniper, which has treated over 100,000 Australian women with semaglutide-based weight management programs. The STEP 1 trial that established semaglutide's efficacy recruited a predominantly female population (74.1% women), giving us meaningful sex-specific data. Women in the trial achieved an average 14.9% body weight loss over 68 weeks. The most important women-specific consideration is muscle preservation: GLP-1-induced appetite suppression creates a caloric deficit that can accelerate muscle loss if protein intake is inadequate. Women entering perimenopause are already at elevated risk of sarcopenia (age-related muscle loss) — a GLP-1 protocol without deliberate high-protein nutrition can worsen this trajectory. The optimal GLP-1 protocol for women integrates deliberate protein targeting (minimum 1.8g per kg bodyweight), resistance training, and creatine supplementation to preserve lean mass during the fat loss phase.

Perimenopause typically begins in the mid-to-late 40s and is characterised by declining oestrogen and progesterone, increasing FSH, and significantly reduced GH secretion. The reduction in GH during this phase contributes to increased visceral fat accumulation, reduced lean mass, impaired sleep architecture, and reduced skin collagen — changes that are often attributed entirely to oestrogen decline but are substantially driven by GH deficiency. Ipamorelin/CJC-1295, by stimulating physiological GH pulses (particularly during deep sleep), can address the GH component of perimenopausal changes without interfering with oestrogen pathways. Reported benefits in perimenopausal women using GH secretagogues include improved sleep quality (often the first noticeable effect), improved body composition, reduced joint discomfort, and improved skin quality. This does not replace oestrogen therapy where indicated — the two address different biological pathways — but represents a meaningful addition to the perimenopausal management toolkit.

The gut-hormone axis is increasingly recognised as central to women's health. Oestrogen influences gut microbiome composition (via the 'estrobolome'), intestinal permeability, and inflammatory tone — and these relationships run bidirectionally. Women with endometriosis have a significantly elevated rate of irritable bowel syndrome and intestinal permeability. BPC-157's gut-healing mechanism — promoting mucosal repair, reducing intestinal inflammation, and restoring barrier function — makes it directly relevant to this population. While no published trials have specifically examined BPC-157 in endometriosis or hormonal gut dysfunction, the mechanism rationale is strong and growing anecdotal evidence supports its use in this context. Women experiencing GI symptoms alongside hormonal imbalances may benefit from BPC-157 as part of an integrated approach, combined with gut microbiome support and appropriate hormone management.

Body composition differences between men and women — specifically the higher average body fat percentage in women — affect the distribution volume of some peptides. Women typically achieve equivalent biological effects at lower absolute doses than men for some peptide classes. For GLP-1 therapy, the titration schedule is standardised and does not differ by sex — the dose adjustment is based on tolerance and response. For GH secretagogues, starting at the lower end of the recommended range (100 mcg each of Ipamorelin and CJC-1295) is appropriate for most women and can be titrated based on IGF-1 blood work. For BPC-157, standard dosing (250–500 mcg daily) applies to both sexes. The most important dose-related consideration for women is timing around the menstrual cycle: some practitioners adjust GH secretagogue timing in cycling women to align with the luteal phase when GH secretion is naturally lower, though this remains practitioner-preference rather than evidence-based protocol.

Not all telehealth practitioners who prescribe peptides have specific expertise in women's health. When evaluating a prescriber for peptide therapy, look for practitioners who ask specifically about menstrual cycle status, perimenopausal symptoms, hormonal contraceptive use, and whether you are working with a gynaecologist or endocrinologist for any underlying hormonal conditions. Peptide therapy should complement, not replace, appropriate hormonal management where indicated. Clinics that focus on weight management for women (like Juniper) have deep expertise in GLP-1 therapy in the female hormonal context but may be less equipped to manage GH secretagogue protocols. Integrative medicine clinics and longevity-focused practices (like Thrive Rx) typically offer broader peptide expertise but with less gender-specific specialisation. ProtocolHub's clinic comparison tool includes goal filtering that can help identify providers appropriate for women's health-specific peptide protocols.